13F HOLDINGS REPORT
Lynx1 Capital Management LP
Quarter ended Q1 2025 · Filed May 15, 2025 · Accession 0001892688-25-000120
Total Value
$279.2M
Positions
14
Other Managers
1
Confidential Omitted
No
Holdings (14)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | GH RESEARCH PLC | GHRS | 6,443,940 | $71.1M | 25.45% |
| 2 | MERUS N V | N5749R100 | 1,568,841 | $66.0M | 23.65% |
| 3 | PROTAGONIST THERAPEUTICS INC | PTGX | 733,014 | $35.4M | 12.69% |
| 4 | STOKE THERAPEUTICS INC | STOK | 5,291,929 | $35.2M | 12.60% |
| 5 | CULLINAN THERAPEUTICS INC | CGEM | 3,215,722 | $24.3M | 8.72% |
| 6 | ALLOGENE THERAPEUTICS INC | ALLO | 11,057,009 | $16.1M | 5.78% |
| 7 | C4 THERAPEUTICS INC | CCCC | 7,098,133 | $11.4M | 4.07% |
| 8 | TSCAN THERAPEUTICS INC | TCRX | 5,357,347 | $7.4M | 2.65% |
| 9 | PRECISION BIOSCIENCES INC | DTIL | 766,051 | $3.7M | 1.31% |
| 10 | IBIO INC | IBIO | 862,279 | $3.5M | 1.24% |
| 11 | PASSAGE BIO INC | PASG | 9,256,953 | $3.3M | 1.17% |
| 12 | UPSTREAM BIO INC | UPB | 219,247 | $1.3M | 0.48% |
| 13 | NEUPHORIA THERAPEUTICS INC | NEUP | 45,806 | $263,843 | 0.09% |
| 14 | DESIGN THERAPEUTICS INC | DSGN | 65,954 | $254,582 | 0.09% |